Antibody-Drug Conjugate– tag –
-
AstraZeneca/Daiichi Sankyo’s Enhertu Receives EU Approval as First Tumor-Agnostic HER2-Directed ADC
AstraZeneca UK Overview AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), has received EU approval as the first tumor-agnostic HER2-directed therapy for patients with previously treated HER... -
Lonza Expands Commercial ADC Payload-Linker Manufacturing Capacity at Visp to Support Growing Oncology Pipeline
BioPharma APAC Switzerland Overview CDMO giant Lonza has announced significant expansion plans for its commercial antibody-drug conjugate (ADC) payload-linker manufacturing capacity at its Visp, Switzerland, site. This strategic investme... -
FDA Grants Fast Track Designation to Multiple Oncology Drugs in May & June 2026, Including ADC for Metastatic Neuroendocrine Tumors
Oncology News Central USA Overview In May and June 2026, the U.S. FDA granted Fast Track designation to several novel oncology therapies, accelerating their development for serious conditions. Noteworthy designations include Zai Lab Limi... -
FDA Approves Multiple Novel Oncology Drugs in June 2026, Including ADC for Breast Cancer and Combination for Prostate Cancer
Targeted Oncology USA Overview In June 2026, the U.S. FDA granted several new drug approvals and expanded indications in oncology, notably for Gilead Sciences' antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), in two ... -
Lonza Significantly Boosts ADC Manufacturing Capacity at Swiss Visp Site, Expanding Payload-Linker Production and Launching New Commercial Facility by 2028
Fierce Pharma Switzerland Overview Lonza announced a significant expansion of its ADC manufacturing capacity, extending a partnership with a major US drugmaker to meet the growing demand in the antibody-drug conjugate market. At its Visp... -
ADC Therapeutics Completes Enrollment for LOTIS-7 Phase 1b Trial of Zynlonta-Glofitamab Combination, Reporting Interim 89.8% ORR in Relapsed/Refractory DLBCL Patients
BioPharm International Switzerland Overview ADC Therapeutics has completed patient enrollment for the Phase 1b LOTIS-7 trial, evaluating the combination of its CD19-targeted antibody-drug conjugate (ADC) Zynlonta with the bispecific anti... -
ADC Technology Evolves: Data-Driven Design from Antigen Selection to AI-Assisted Engineering Transforms Therapeutic Paradigm
MDPI Unknown Overview Antibody-drug conjugates (ADCs) have evolved into a mature therapeutic platform with exponentially increasing clinical relevance. This review highlights recent advances in ADC design and development, emphasizing the... -
Antibody-Drug Conjugates (ADCs) Show Promise for Epithelioid Hemangioendothelioma (EHE) Treatment: Highlighted at ASCO 2026
EHE Foundation USA Overview Antibody-drug conjugates (ADCs) are gaining significant attention as a promising emerging strategy for treating epithelioid hemangioendothelioma (EHE), a rare and challenging cancer. ADCs deliver potent anti-c... -
Constructive Bio Develops Oral Peptide Pipeline with Novel Membrane Permeability via Unnatural Amino Acids, Advancing ADCs with Genetic Code Expansion for Injectable-to-Oral Shift
Constructive Bio Unknown Overview Constructive Bio is developing a pipeline of oral peptide therapeutics using unnatural amino acids to enable oral bioavailability for drugs previously requiring injection. These engineered peptides featu... -
Major Setback: Pfizer’s Seagen-Acquired ADC Fails Phase 3 in Advanced Lung Cancer
BioPharma Dive USA Overview Pfizer's antibody-drug conjugate (ADC), sigvotatug vedotin, acquired through its Seagen acquisition, failed to meet its primary endpoint of improved overall survival (OS) in a Phase 3 clinical trial for patien...
